Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Inclusion Criteria: * Female or male, treatment naïve patient with ≥50 years of age, with neovascular age-related macular degeneration (nAMD). * Patient or legally acceptable representative (LAR) willing to voluntarily provide signed informed consent for participation in the study. Note: In case where both eyes are affected, data of only one eye \['study eye'\] will be recorded. Selection of the eye to be considered for the purpose of the study \[referred to as 'study eye'\] will be as per the Investigator's discretion. Exclusion Criteria: * Patients fulfilling any of the following criteria are not eligible for this study: * Patient having other eye diseases that could compromise the VA. * Patient with existing or suspected ocular or periocular infection in the study eye. * Patient with an existing intraocular inflammation (IOI). * Patient with uncontrolled glaucoma defined as intraocular pressure \> 25 mmHg despite treatment with anti-glaucoma medication, or according to Investigator's judgment. * Patient who has undergone intraocular surgery within 3 months prior to enrollment in this study. * Patient having scar, fibrosis and atrophy involving the center of the fovea in the study eye.